ADVANCED ENZYME TECHNOLOGIES
|
ADVANCED ENZYME TECHNOLOGIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 11.92 | 9.45 | 10.70 | 13.06 | 11.58 |
| CEPS(Rs) | 15.40 | 12.42 | 14.20 | 16.11 | 14.22 |
| DPS(Rs) | 5.10 | 1.00 | 1.00 | 0.90 | 0.60 |
| Book NAV/Share(Rs) | 118.14 | 110.45 | 97.31 | 86.67 | 74.86 |
| Tax Rate(%) | 27.08 | 26.02 | 27.63 | 28.00 | 25.74 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 32.87 | 29.09 | 38.19 | 46.74 | 45.74 |
| EBIT Margin(%) | 30.73 | 26.57 | 32.80 | 42.75 | 41.26 |
| Pre Tax Margin(%) | 30.07 | 25.93 | 32.25 | 42.23 | 40.34 |
| PAT Margin (%) | 21.92 | 19.18 | 23.34 | 30.41 | 29.96 |
| Cash Profit Margin (%) | 27.57 | 25.65 | 29.93 | 36.18 | 35.76 |
| Performance Ratios | |||||
| ROA(%) | 9.34 | 7.78 | 10.28 | 14.27 | 14.98 |
| ROE(%) | 10.72 | 8.94 | 12.04 | 16.77 | 17.61 |
| ROCE(%) | 14.78 | 12.26 | 16.66 | 22.93 | 23.21 |
| Asset Turnover(x) | 0.43 | 0.41 | 0.44 | 0.47 | 0.50 |
| Sales/Fixed Asset(x) | 0.71 | 0.65 | 0.68 | 0.69 | 0.70 |
| Working Capital/Sales(x) | 0.89 | 0.84 | 0.98 | 1.11 | 1.41 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.42 | 1.55 | 1.47 | 1.44 | 1.43 |
| Receivable days | 58.11 | 63.55 | 60.03 | 59.04 | 54.83 |
| Inventory Days | 79.59 | 82.55 | 73.90 | 63.79 | 64.49 |
| Payable days | 50.47 | 58.32 | 55.08 | 45.81 | 43.59 |
| Valuation Parameters | |||||
| PER(x) | 29.15 | 24.52 | 26.37 | 26.40 | 12.36 |
| PCE(x) | 22.57 | 18.65 | 19.86 | 21.40 | 10.07 |
| Price/Book(x) | 2.94 | 2.10 | 2.90 | 3.98 | 1.91 |
| Yield(%) | 1.47 | 0.43 | 0.35 | 0.26 | 0.42 |
| EV/Net Sales(x) | 6.04 | 4.59 | 5.46 | 7.32 | 3.47 |
| EV/Core EBITDA(x) | 15.55 | 13.56 | 13.83 | 15.22 | 7.37 |
| EV/EBIT(x) | 19.63 | 17.24 | 16.61 | 17.27 | 8.41 |
| EV/CE(x) | 2.79 | 1.99 | 2.63 | 3.71 | 1.78 |
| M Cap / Sales | 6.23 | 4.79 | 5.96 | 7.68 | 3.60 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 15.39 | 2.13 | 5.49 | 13.03 | 5.81 |
| Core EBITDA Growth(%) | 32.44 | -12.46 | -13.43 | 15.51 | 11.01 |
| EBIT Growth(%) | 33.42 | -17.32 | -18.19 | 16.08 | 9.61 |
| PAT Growth(%) | 31.85 | -16.10 | -18.17 | 13.71 | 14.79 |
| EPS Growth(%) | 26.19 | -11.68 | -18.11 | 12.82 | 16.39 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 |
| Current Ratio(x) | 7.61 | 9.31 | 10.00 | 7.64 | 6.31 |
| Quick Ratio(x) | 6.22 | 7.71 | 8.00 | 6.25 | 4.96 |
| Interest Cover(x) | 46.58 | 41.36 | 58.89 | 82.76 | 44.94 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | - | - | 0.02 |
Compare Financial Ratios of peers of ADVANCED ENZYME TECHNOLOGIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ADVANCED ENZYME TECHNOLOGIES | ₹3,786.7 Cr | 5.3% | 11.1% | -8.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹402,284.0 Cr | -0% | -0.4% | 10.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹183,268.0 Cr | 1.4% | 4.1% | 50.3% | Stock Analytics | |
| CIPLA | ₹122,253.0 Cr | 0.5% | 1.6% | 1.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹113,988.0 Cr | -1.2% | 7.1% | 18.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,921.0 Cr | 1.7% | 1.2% | 1.5% | Stock Analytics | |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ADVANCED ENZYME TECHNOLOGIES | 5.3% |
11.1% |
-8.2% |
| SENSEX | -0.7% |
3% |
5% |
You may also like the below Video Courses
